An Open-Label, Multi-Centre, Rollover Study to Characterise Long-Term Safety and Efficacy of Etavopivat In Adults, Adolescents and Children Who Have Sickle Cell Disease or Thalassaemia And Have Completed A Treatment Period in An Etavopivat Study

drug protocol number
NN7535-7822
drug sponsor
Novo Nordisk
drug study
Etavopivat
drug trial site
Prince Mohammad Bin Naser Hospital (Jazan)
drug status
Ongoing
drug phase